MarthaMariePachecoMD
Pediatric Hematology & Oncology • Boise, IDPediatric Hematologic Oncology
Physician
Dr. Pacheco is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
St. Luke's Children's Cancer Institute
100 E Idaho St
Boise, ID 83712Phone+1 208-381-2782- Is this information wrong?
Education & Training
University of Texas Southwestern Medical CenterFellowship, Pediatric Hematology/Oncology, 2006 - 2009- University of Texas Southwestern Medical CenterResidency, Pediatrics, 2003 - 2006
University of Texas Southwestern Medical SchoolClass of 2003
Certifications & Licensure
ID State Medical License 2005 - 2025
TX State Medical License 2005 - 2022- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
- Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas Start of enrollment: 2013 Jun 17
- Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Start of enrollment: 2013 Nov 13
Publications & Presentations
PubMed
- 1 citationsBrentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma.Christopher J Forlenza, Jaclyn Rosenzweig, Audrey Mauguen, Ilia Buhtoiarov, Branko Cuglievan, Hema Dave, Rebecca J Deyell, Jamie E Flerlage, Anna K Franklin, Jennifer ...> ;Blood Advances. 2023 Jul 11
- 9 citationsHigh risk of relapsed disease in patients with NK/T cell chronic active Epstein-Barr virus disease outside of Asia.Blachy J. Dávila Saldaña, Tami D John, Challice L. Bonifant, David Buchbinder, Sharat Chandra, Shanmuganathan Chandrakasan, Weni Chang, Leon Chen, Hannah L Elfassy, As...> ;Blood Advances. 2021 Oct 20
- High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas.Hatanpaa, K. J.,Hu, T.,Vemireddy, V.,Foong, C.,Raisanen, J. M.,Oliver, D.,Hiemenz, M. C.,Burns, D. K.,White, C. L.,Whitworth, L. A.,Mickey, B.,Stegner, M.,Habib, A. A....> ;J. Neurooncol.. 2014 Feb 13
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Children's Medical Center DallasDallas, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
